Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise against tough lymphoma

NCT ID NCT04067037

Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy (AVD) can improve outcomes for people with advanced classical Hodgkin lymphoma who have not yet been treated. About 60 adults aged 18 to 75 will receive the combination for up to six cycles. The main goal is to see how many achieve a complete metabolic response, meaning no signs of active cancer on scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
camrelizumab (an immunotherapy drug) combined with chemotherapy (epirubicin, vincristine, dacarbazine)
What this could lead to
If successful, this combination could become a new first-line treatment option for advanced Hodgkin lymphoma, potentially improving response rates without long-term medication.
What could go wrong
This is a small, early-phase (phase 2) trial with only 60 participants and no comparison group. Results may not confirm benefit, and side effects from immunotherapy plus chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 to 75 years old (including 18 and 75) 2. Diagnosed as advanced classical hodgkin's lymphoma based on histopathology 3. Subjects must be untreated (Ann Arbor Stage III/IV or Ann Arbor II with B symptoms along with mediastinal big tumor or extranodal changes) 4. No receiving chemotherapy before enrollment 5. Having at least one measurable lesions 6. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2 7. Life expectancy no less than 3 months 8. enough main organ function 9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study 10. Agreeing to sign the written informed consents Exclusion Criteria: 1. Diagnosed as nodular lymphocyte predominant lymphoma or grey-zone lymphoma 2. Diagnosed as central nervous system lymphoma 3. usage of immunosuppressants before enrollment and the dose of immunosuppressant used \>10mg / day oral prednisone for more than 2 weeks 4. Previously treated with anti-PD-1/PD-L1/PD-L2/CTLA-4 5. Active autoimmune disease 6. Vaccination with anti-tumor vaccine or other immune treatments less than 3 months 7. Serious surgery and trauma less than two weeks 8. Other malignant tumor history or active malignant tumor need be treated 9. Systemic therapy for serious acute/chronic infection 10. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months 11. Active tuberculosis 12. Vaccination with live attenuated vaccine less than 4 weeks 13. HIV-positive, AIDS patients and untreated active hepatitis 14. Researchers determine unsuited to participate in this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma

Contacts and locations

Locations

  • An Yang Tumor Hospital

    Anyang, Henan, 455000, China

  • Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

    Zhengzhou, Henan, China

  • The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology

    Luoyang, Henan, 471003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.